Drug Safety Communication: Initial safety trial results find increased risk of serious heart-related problems and cancer with Xeljanz, Xeljanz XR (tofacitinib)

Drug Safety Communication

If your email program has trouble displaying this email, view as a webpage. Drug Safety Communication The U.S. Food and Drug Administration (FDA) is alerting the public that preliminary results from a safety clinical trial show an increased risk of serious heart-related problems and cancer with the arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib) compared to another type of medicine called tumor necrosis factor (TNF) inhibitors.  FDA required the safety trial, which also investigated other potential risks including blood clots in the lungs and death.  Those final results are not yet available.  We will evaluate the clinical trial results we have received to date and will work with the drug manufacturer to obtain further information as soon as possible.  We will communicate our final conclusions and recommendations when we have completed our review or have more information to share. For more information, read the complete Drug Safety Communication.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA